(Q33366244)

26 July 2017

A phase II study of bortezomib in the treatment of metastatic malignant melanoma (English)

1 reference

26 July 2017

10

Alex A Adjei

1 reference

26 July 2017

11

Charles Erlichman

1 reference

26 July 2017

2

Susan M Geyer

1 reference

26 July 2017

1

Svetomir N Markovic

1 reference

26 July 2017

8

Tom Fitch

1 reference

26 July 2017

9

Patricia Lorusso

1 reference

26 July 2017

Fitzroy Dawkins

3

1 reference

26 July 2017

William Sharfman

4

1 reference

26 July 2017

Mark Albertini

5

1 reference

26 July 2017

William Maples

6

1 reference

26 July 2017

Paula M Fracasso

7

1 reference

26 July 2017

language of work or name

English

0 references

publication date

1 June 2005

1 reference

26 July 2017

1 reference

26 July 2017

103

1 reference

26 July 2017

2584-2589

1 reference

26 July 2017

12

1 reference

Preclinical and clinical evaluation of proteasome inhibitor PS-341 for the treatment of cancer

26 July 2017

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21108

7 January 2021

Protease inhibitor-induced apoptosis: accumulation of wt p53, p21WAF1/CIP1, and induction of apoptosis are independent markers of proteasome inhibition

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21108

7 January 2021

Proteasome inhibition in cancer: development of PS-341.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21108

7 January 2021

Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21108

7 January 2021

How proteolysis drives the cell cycle

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21108

7 January 2021

Protein degradation in human disease.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21108

7 January 2021

https://api.crossref.org/works/10.1002%2FCNCR.21108

1 reference

7 January 2021

The ubiquitin-proteasome pathway is required for processing the NF-kappa B1 precursor protein and the activation of NF-kappa B

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21108

7 January 2021

Ubiquitin-dependent proteolysis: its role in human diseases and the design of therapeutic strategies

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21108

7 January 2021

Regulation of apoptosis by the ubiquitin and proteasome pathway.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21108

7 January 2021

Clinical update: proteasome inhibitors in hematologic malignancies

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21108

7 January 2021

A phase 2 study of bortezomib in relapsed, refractory myeloma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21108

7 January 2021

Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21108

7 January 2021

26S proteasome inhibition induces apoptosis and limits growth of human pancreatic cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21108

7 January 2021

Chemosensitization of pancreatic cancer by inhibition of the 26S proteasome

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21108

7 January 2021

Proteasome inhibitors in the treatment of B-cell malignancies

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21108

7 January 2021

Molecular pathways that modify tumor radiation response

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21108

7 January 2021

Enhancement of radiosensitivity by proteasome inhibition: implications for a role of NF-kappaB.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21108

7 January 2021

Identifiers

DOI

10.1002/CNCR.21108

1 reference

26 July 2017

1 reference